Graham Capital Management L.P. increased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 165.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,676 shares of the company's stock after acquiring an additional 26,000 shares during the quarter. Graham Capital Management L.P. owned approximately 0.15% of Castle Biosciences worth $1,111,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of CSTL. Covestor Ltd acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at $25,000. R Squared Ltd bought a new stake in Castle Biosciences during the fourth quarter valued at about $42,000. KLP Kapitalforvaltning AS bought a new position in Castle Biosciences during the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock worth $158,000 after acquiring an additional 604 shares during the period. Finally, Oak Harvest Investment Services bought a new stake in Castle Biosciences in the fourth quarter valued at about $206,000. 92.60% of the stock is currently owned by institutional investors.
Castle Biosciences Stock Down 2.2%
Shares of CSTL traded down $0.37 during trading hours on Monday, reaching $16.38. The stock had a trading volume of 41,149 shares, compared to its average volume of 404,660. Castle Biosciences, Inc. has a 12 month low of $15.70 and a 12 month high of $35.84. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $472.81 million, a price-to-earnings ratio of 82.05 and a beta of 1.19. The firm has a 50-day simple moving average of $19.49 and a 200 day simple moving average of $24.99.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). The firm had revenue of $87.99 million for the quarter, compared to analysts' expectations of $80.40 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. Equities research analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, insider Derek J. Maetzold sold 1,236 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $21.52, for a total transaction of $26,598.72. Following the completion of the transaction, the insider now owns 74,627 shares of the company's stock, valued at approximately $1,605,973.04. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 27,454 shares of company stock worth $553,030 over the last ninety days. 6.50% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several research analysts recently issued reports on CSTL shares. Lake Street Capital reduced their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group lowered their price objective on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird boosted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the stock a "buy" rating in a report on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $37.50.
Check Out Our Latest Analysis on CSTL
About Castle Biosciences
(
Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
